

NOVO-NORDISK AS B

ISIN: DK0060534915 WKN: - Asset Class: **Stock**

Company

2023/02/06 16:59:38



Price

958.00

DKK

Difference

1.75%(16.50)



Contact Details

NOVO NORDISK A/S Tel: 45-44-44-88-88

-- Fax: -

Novo Allé 1 Web: <http://www.novonordisk.com>

2880 Bagsværd E-mail: -

Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	108,194,000,000		85,595,000,000		65,809,000,000	
Common stock capital		456,000,000		462,000,000		470,000,000
Fixed assets	133,063,000,000		108,913,000,000		79,113,000,000	
Equity capital of a company		83,486,000,000		70,746,000,000		63,325,000,000
Cash and cash equivalents	12,653,000,000		10,720,000,000		12,757,000,000	
Accrued liabilities		5,352,000,000		5,654,000,000		5,925,000,000
Other assets	-		-		-	
Current liabilities		120,940,000,000		99,516,000,000		70,273,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		36,831,000,000		24,246,000,000		11,324,000,000
Different income		-		-		-
Other liabilities		100,000,000		360,000,000		0
Total assets	241,257,000,000	241,257,000,000	194,508,000,000	194,508,000,000	144,922,000,000	144,922,000,000

Balance notes

	2022	2021	2020
Accounting standard	IFRS	IFRS	IFRS
Employees	54,393	47,792	45,323
Equity ratio	34.60%	36.37%	43.70%
Debt-equity ratio	188.98%	174.94%	128.85%

Others

	2022	2021	2020
Tax Expense Rate	19.55%	19.16%	20.75%

NOVO-NORDISK AS B

ISIN: DK0060534915 WKN: - Asset Class: **Stock**

Income statement

	2022	2021	2020
Turnover	176,954,000,000	140,800,000,000	126,946,000,000
Net income	55,525,000,000	47,757,000,000	42,138,000,000
EBIT	9,350,342,400	7,967,769,600	7,147,929,600
Operating income before taxes	69,251,000,000	59,104,000,000	52,981,000,000
Cash Flow	78,887,000,000	55,004,000,000	51,969,000,000
Net interest income	-320,000,000	-180,000,000	-203,000,000
Research and development expenses	21,761,000,000	16,292,000,000	13,713,000,000
Income taxes	13,537,000,000	11,323,000,000	10,992,000,000
Result from investments in subsidiaries, associates and other	-189,000,000	-24,000,000	149,000,000
Revenues per employee	437,237	395,956	376,443

Board of Directors

Helge Lund	Chairman of Supervisory Board
Martin MacKay	Member of Supervisory Board
Sylvie Grégoire	Member of Supervisory Board
Andreas Fibig	Member of Supervisory Board
Elisabeth Christensen	Member of Supervisory Board
Henrik Poulsen	Member of Supervisory Board
Jeppe Fonager Christiansen	Member of Supervisory Board
Kasim Kutay	Member of Supervisory Board
Laurence Debroux	Member of Supervisory Board
Liselotte Hyveled	Member of Supervisory Board
Mette Bøjer Jensen	Member of Supervisory Board
Thomas Rantzaу	Member of Supervisory Board

Members of Management Board

Lars Fruergaard Jørgensen	Chairman of Managing Board
Camilla Sylvest	Member of Executive Committee
Doug Langa	Member of Executive Committee
Henrik Wulff	Member of Executive Committee
Karsten Munk Knudsen	Member of Executive Committee
Ludovic Helfgott	Member of Executive Committee
Marcus Schindler	Member of Executive Committee
Martin Horst Lange	Member of Executive Committee
Maziar Mike Doustdar	Member of Executive Committee
Monique Carter	Member of Executive Committee